Key Highlights
- MGRX shares skyrocketed more than 129% during Monday’s trading session following SEC disclosures about CEO compensation.
- Jacob Cohen, the company’s chief executive, was awarded 500,000 bonus shares under his compensation agreement.
- An additional 200,000 shares were transferred to The Tiger Cub Trust, an entity under Cohen’s control, increasing the trust’s holdings to 805,000 shares.
- More than 107 million shares traded hands, vastly exceeding the typical three-month daily average of 208,000 shares.
- Despite Monday’s surge, the stock plummeted 54.51% the previous Friday and remains down 78.11% for the year.
- Analyst sentiment remains decidedly negative with a “Strong Sell” consensus and no current price targets available.
Shares of Mangoceuticals (MGRX) experienced an extraordinary surge exceeding 129% during Monday’s session after regulatory filings disclosed that Chief Executive Jacob Cohen was granted 500,000 shares as bonus compensation.
The same SEC documentation revealed that Cohen moved an additional 200,000 shares into The Tiger Cub Trust, which operates under his authority, boosting the trust’s total position to 805,000 shares. The simultaneous disclosure of both transactions ignited significant market interest.
The dramatic Monday rally came on the heels of a brutal Friday session that saw shares plummet 54.51%. Despite the recent pop, MGRX continues to struggle with a 78.11% decline year-to-date and a staggering 96.59% drop over the trailing twelve months.
Trading activity exploded on Monday with volume exceeding 107 million shares—a dramatic acceleration compared to the stock’s three-month daily average of approximately 208,000 shares.
According to MarketBeat data from late October 2025, the stock was trading around $2.33 per share at its most recent recorded close. Notably, no active analyst price targets are currently available for the stock.
Legal Action and Intellectual Property Progress
Beyond executive compensation matters, Mangoceuticals has been active on multiple operational fronts. The company initiated civil litigation against its former technology collaborator, Clarity Ventures, Inc., pursuing damages that exceed $73 million. The lawsuit centers on alleged deficiencies in technology services and platform development deliverables.
Regarding innovation efforts, the company submitted a PCT international patent application in February covering MGX-0024, a proprietary antiviral additive formulation designed for incorporation into animal feed and water supplies. The filing, submitted on February 26, 2026, seeks comprehensive global patent protection.
Commercial Activities
The company’s injectable testosterone replacement therapy (TRT) subscription service, offered at a $99 monthly price point, has demonstrated encouraging traction. Company leadership reported remarkable 336% month-over-month revenue growth since mid-December, accompanied by a 54% reduction in customer acquisition expenses.
Mangoceuticals has also expanded its product portfolio with MangoRx Direct and PeachesRx Direct, both introduced in November 2025. These digital platforms facilitate patient access to GLP-1 obesity medications including Zepbound and Wegovy, with monthly costs beginning around $499 on a direct cash-pay model.
Notwithstanding these business developments, analyst coverage remains sparse and pessimistic. MarketBeat data shows one Sell rating with zero Buy or Hold recommendations currently active for the stock.
The overall analyst perspective stands at “Strong Sell,” with no major financial institutions publishing upgrades, downgrades, or fresh price objectives in recent months.
The latest available closing price on record stands at approximately $2.33 per share as of late October 2025.
